INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...
Arcutis has reported positive topline data from the INTEGUMENT-INFANT Phase II trialassessing Zoryve (roflumilast) cream 0.05 ...
WESTLAKE VILLAGE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Biotherapeutics (ARQT) announced the enrollment of the last subject in the INTEGUMENT-INFANT Phase 2 open-label clinical study, which is evaluating the safety and tolerability of ...
Arcutis Biotherapeutics has announced promising results from its Phase 3 INTEGUMENT-OLE study concerning the investigational ZORYVE cream for treating atopic dermatitis (AD). The long-term study ...
Full data results will be presented at future medical conferences and in peer-reviewed journals. The INTEGUMENT-1 study met the primary endpoint and all secondary endpoints. Topline results were ...
Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older. Roflumilast cream 0.15% is a ...
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4 Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results